980. Chlamydia Trachomatis Retesting in a GUM Clinic in the West of Ireland
Session: Poster Abstract Session: Clinical Studies of Bacterial Infection
Saturday, October 22, 2011
Room: Poster Hall B1

Background:

Chlamydia retesting at 3 months following treatment is recommended by 2010 CDC guidelines. If this is not possible, clinicians should retest at next presentation for care in the year following initial treatment. Most chlamydia infections after initial treatment are from re-infection and not initial treatment failure. The British Association for Sexual Health and HIV makes no specific recommendations for repeat testing, although the UK Department of Health Chlamydia screening programme recommends Chlamydia screening for under 25s annually or with any new contacts. Repeat infections confer elevated risk for pelvic inflammatory disease and other complications.

Methods:

All females diagnosed with Chlamydia attending between October 2008-2010 were advised to attend for repeat Chlamydia testing 3-6 months after initial diagnosis and treatment. Chart review assessed compliance with this recommendation and follow up results.

Results:

93 females were diagnosed with Chlamydia infection. The mean age was 24.3 years, (range 16-46 years). 37 (39.8%) returned and tested negative for Chlamydia. (Of note, some tested later than the 6 months recommendation). 55 (59.1%) did not return. 1 person (1.1%) reported she repeated her test at her family doctor and was positive for chlamydia 1 year after initial infection.


Conclusion:

There was a low rate of chlamydia reinfection amongst women previously treated for same. This may represent a lower background rate of chlamydia in the Irish healthcare setting as compared to that reviewed by the CDC. Irish chlamydia data from the HPSC 2005 report suggest prevalence rates from 5.4-6.3%. In 2008 there were 6290 cases of chlamydia reported to the HSPC. 2009 CDC data describes annual chlamydia rates of 409.2 per 100,000 population- 592.2 per 100,000 women and 219.3 in men. The incidence rate of chlamydia in this sample group was not necessarily higher than that of the previously untreated population. We found no evidence suggesting recall and retesting this population would lead to increased rates of chlamydia detection. This has implications for service design and suggests focussing chlamydia screening on all attenders regardless of previously documented chlamydia.


Subject Category: C. Clinical studies of bacterial infections and antibacterials including sexually transmitted diseases and mycobacterial infections (surveys, epidemiology, and clinical trials)

Clare Coleman, PhD, Department of Genitourinary Medicine, Galway, Ireland and Katie McFaul, MRCPI, Department of Infectious Diseases, University Hospital Galway, Galway, Ireland

Disclosures:

C. Coleman, None

K. McFaul, None

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.